



Press release from Emotra AB (publ)
Göteborg, November 26, 2021

Emotra AB: Emotra finalizes its acquisition of NeuraMetrix

As announced on August 31, 2021, Emotra AB (publ) has agreed to acquire all outstanding shares in NeuraMetrix Inc. Today, Emotra AB concluded the transfer of ownership of all shares in NeuraMetrix.

The purchase price for all of these shares amounted to approximately MSEK 94 and this price was paid through the issue of 276,241,035 new shares in Emotra AB. Pursuant to the authority granted to the board of directors of Emotra AB by the extraordinary shareholder meeting held on October 8, 2021, the board has today decided to issue 276,241,035 new shares. Only shareholders in NeuraMetrix Inc. have the right to subscribe to these shares. The issue price for the Replacement shares will be 0.34 SEK/share, which was calculated as the volume-weighted average price for Emotra's shares during a 10-day trading period on Spotlight, from August 17 through August 30, 2021.

Upon completion of the acquisition of all shares in NeuraMetrix, Emotra's present shareholders will own approximately 23 percent of the merged company, while NeuraMetrix's present shareholders will obtain an equity stake of about 77 percent.

Background and justification of the acquisition

This transaction will deliver a greater opportunity for Emotra's existing shareholders to realise a return on their investment in the Company. It is the board's opinion that this new constellation will provide Emotra with a greater opportunity to create value for its shareholders. The acquisition is expected to generate synergies, since the two companies complement each other perfectly as far as goals, markets, customers, geographical focus, and the problems their respective technologies solve. Consequently, both boards of directors feel these efforts would be facilitated by working together as one company.

At present, NeuraMetrix already generates income and this transaction will provide the merged company with the means to maximise its commercial potential. A presentation of the merged company's operations will be presented later.

For further information about Emotra, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se daniel@emotra.se

About NeuraMetrix

NeuraMetrix discovered that the way we type on a keyboard is one of our strongest habits. Thus, this method is hard coded in our brain. When the brain is attacked by a disease, this hard coding breaks down and the behaviour varies more. However, this process is very slow and progresses in very small increments. NeuraMetrix has invented a method to measure how strong this habit is, and this measurement can be used to diagnose and monitor both neurological diseases and psychiatric disorders. NeuraMetrix has translated this discovery and invention into a software system, NeuraMetrix TC (Typing Cadence), that monitors neurological status to enable better care of patients with different neurological diseases and psychiatric disorders. NeuraMetrix TC is installed on the patient's computer, where it continuously and in the background monitors the rhythm of the patient's typing on the keyboard. Measurement is performed on a scale of milliseconds, which enables the discovery of very subtle changes in cognitive and motor faculties. Many of NeuraMetrix's

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for identifying hyporeactive patients.



research advisors believe that this system is so sensitive, it could identify Alzheimer's disease up to 20 years sooner than current methods are capable of.

The application areas include monitoring of Parkinson's, Alzheimer's, bipolar disorders, multiple sclerosis, depression, and more. NeuraMetrix has built up a database comprising more than 1 billion data points from more than 600 people. NeuraMetrix's IP portfolio is strong, with 4 approved US patents and two more applications that will be submitted in October this year. Furthermore, the company has been able to leverage its history in the IT security sector to protect its product from illegal use.

NeuraMetrix's origins can be traced to the USA and the company was founded in 2013. NeuraMetrix has access to a comprehensive network of scientific partners and potential clients in both the USA and Europe. On top of that, NeuraMetrix has representatives in South America and Southeast Asia.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for identifying hyporeactive patients.